Archive: 24/04/2015
NASH associated with a 50 percent higher chance of death compared with NAFLD
Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those ...
Apr 24, 2015
Grazoprevir-elbasvir combo shows high cure rate for patients with chronic HCV
Once-daily oral grazoprevir/elbasvir combination therapy, taken without interferon or ribavirin for 12 weeks, demonstrated high sustained virologic response rates for treatment-naïve patients with cirrhotic or non-cirrhotic ...
Apr 24, 2015
Once-daily grazoprevir/elbasvir is effective in patients infected with chronic hepatitis C
Results presented today at The International Liver Congress 2015 show that a 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir (GZR/EBR) is effective and well-tolerated in treatment-naive (TN) patients ...
Apr 24, 2015
Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C
A new study presented today at The International Liver Congress 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; ...
Apr 24, 2015
Cancer rates among patients with hepatitis C are increased compared to those not infected
Results announced today at The International Liver Congress 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an ...
Apr 24, 2015